2 бет - Ең жақсы Фибросканинг дәрігерлері - ЖОҒ-43 дәрігерлер

Dr. Kayihan Engin is a Radiation Oncologist. He earned his medical degree from Uludağ University Medical College in 1983. He completed his residency in Radiation Oncology at the Center of Oncology & Nuclear Medicine in Istanbul in 1990. From 1990 to 1994, he pursued a post-doctoral fellowship in Thermoradiotherapy at Thomas Jefferson University in the USA.

Dr. Engin has held key academic and leadership roles. He served as Professor, Chairman, and Faculty Accreditation Coordinator at Uludağ University Medical College from 1991 to 2005. He was also Professor and Director at Anadolu Medical Center between 2004 and 2017. Since 2017, he has led the Oncological Sciences departments at Ceylan International and Medicana Bursa Hospitals. Dr. Engin is known for his work in improving cancer treatment and medical education standards in Turkey.

Dr. Chaitainya Borde is a nuclear medicine specialist with 12 years of clinical experience. He is skilled in advanced nuclear scans, PET-CT imaging, and nuclear cardiology. He works in both diagnostic and therapeutic nuclear medicine.

Dr. Borde has performed over 30,000 PET scans. He has managed more than 1,000 thyroid cancer patients. He is experienced in radioiodine and Lu-177 RN therapies. He has also published research papers in respected medical journals, showing his dedication to academic work.

Dr. Shruti Kate is an experienced oncologist. She specializes in treating lung, breast, gynecological, and genitourinary cancers. She earned her MBBS from Lady Hardinge Medical College. She completed her MD in Internal Medicine at Maulana Azad Medical College. She also holds a DM in Medical Oncology from Tata Memorial Hospital, Mumbai.

Dr. Kate has managed both conservative and surgical cancer treatments. She is skilled in complex procedures such as the Whipple surgery. She is a member of several leading oncology societies, including ASCO, ESMO, IASCLC, ISMPO, and IOS. Her research on lung cancer received the only travel award from India at the 2018 World Conference on Lung Cancer.

Dr. Sridhar P.S. is a skilled radiation oncologist. He earned his Bachelor of Medicine from Mysore University. He completed his MD in Radiotherapy at Banaras Hindu University. He also holds a Diplomate of the National Board in Radiotherapy. This shows his advanced training and dedication to quality care.

Dr. Sridhar is a member of several professional groups. These include the Association of Radiation Oncology of India, Society for Neuro-Oncology, Bangalore Oncology Group, and the Indian Association of Hyperthermia Oncology. He is known for his effective cancer treatments and focus on new therapies. His work has made a positive impact in the field of oncology.

Dr. Antonio Cubillo Gracián is a specialist in Medical Oncology. He has broad teaching and clinical experience at USP CEU and HM CIOCC. He has directed postgraduate research as Director of the Master’s in Clinical and Applied Research in Oncology. Since 2009, he has tutored more than 100 students, residents, and rotating staff.

Dr. Cubillo has advanced oncology education by teaching subjects such as General Medical Pathology, Oncology, Bioethics, and Pathophysiology. He has organized international courses on digestive neoplasms. He has also worked with leading institutions, including MD Anderson Cancer Center. His academic leadership and clinical mentorship have set high standards in oncology training and research.

2001 жылы доктор Серткая Кония Мерам Ғылым орта мектебін бітіріп, сол жылы Гази университетінің медицина факультетіне түсіп, 2008 жылы бітірді. 2014 жылы Хайдарпаша Нумуна оқу және зерттеу ауруханасында урология мамандығын аяқтап, урология маманы атанды.

Маман болғаннан бері ол Андрологияның қосымша саласына назар аударып, әртүрлі оқыту сессиялары мен конференцияларға қатысып, әлемнің жетекші Андрология профессорларымен бірге операциялар жасаған. 2017 жылы Еуропа Урология қауымдастығының жүргізген жазбаша және ауызша емтихандарынан өтіп, "FEBU" атағын алды.

2020 жылы доктор Серткая Урология доценті атағына ие болды. 2008 жылы басталған Урология және Андрологиядағы сапары 2022 жылы негізін қалаған Andro Expertise Ерлер денсаулығы және эстетика орталығында жалғасуда. Ол өз клиникасында пациенттерді қабылдап, серіктес ауруханаларда операциялар жүргізеді.

Membership in societies:

Expert of scientific journals 

Close co-operation with leading surgeons

Membership of the German Medical Association 

Specialities:

Introduction of new and modern techniques in the field of oncological surgery
General and visceral surgery

Minimally invasive surgery

Gastrointestinal oncology surgery

Oncological surgery

Haemorrhoids treatment

Additional clinical specialisation in minimally invasive and hernia surgery

Surgery and transplantation of the pancreas

Work Experience:

2005: Specialist in the field of surgery

2008: Appointed Senior Consultant specialising in pancreatic surgery and transplantation

2010: Coordinator of the Pancreatic Cancer Centre (Oncocert)

2013: Specialist in visceral surgery

2014: Managing Senior Physician, additional clinical specialisation in minimally invasive and hernia surgery

2019: Chief Surgeon of the Colorectal Cancer Centre Bochum (the first certified colorectal cancer centre in Germany and one of the first certified leading colorectal centres in Europe)

2021: Chief Surgeon of the Department of Surgery at the Academic Hospital Solingen

Thanks to the professor and his team, the department has been modernised by introducing modern surgical methods of treatment and especially improved methods of post-operative recovery. The Department of Surgery at the Solingen Clinic is now further expanding its focus on minimally invasive surgery in the direction of robotics. The clinic has allocated a huge budget for the purchase of state-of-the-art equipment in order to offer patients a full range of surgical methods for the treatment of benign and malignant diseases of the oesophagus, lungs, stomach, liver, pancreas and intestines according to current guidelines and using the most modern technical equipment.

Professor Schenker is an active researcher and lecturer. He lectures at medical universities and organises seminars and workshops for colleagues. He cooperates closely with the Cancer Centre, the Pancreatic Cancer Treatment Centre, the Intestinal Cancer Treatment Centre and the Interregional Trauma Centre.

Education:

• Bachelor of Science (MD): Faculty of Medicine, Uludag University, 1989

Specialized Education and Experience:

• General Surgery Specialist Degree: Ankara Numune Training and Research Hospital, 1997
• Fellowship: Gastroenterology Surgery, Türkiye High Specialization Hospital, 2005

Academic Career:

• Associate Professor: General Surgery, Inonu University, 2011
• Professorship: General Surgery, İnönü University, 2017

A specialist in the digestive system through MIR from the Hospital Clinic of Barcelona and a Doctor of Medicine from the University of Barcelona, he received his PhD from the University of Barcelona.

He completed his postgraduate training in the Gastroenterology Service of the Barcelona Hospital Clinic and then in the Department of Gastroenterology at Case Western Reserve University (Cleveland, USA), where he conducted cutting-edge research on inflammatory bowel diseases (IBD, Crohn's disease and ulcerative colitis).

From 2004 to 2011 he worked in the Gastroenterology Department of the Barcelona Hospital Clinic / IDIBAPS, and since 2011 he has worked as a specialist doctor in the Digestive System Department of the Teknon Medical Center in Barcelona.

He was a member of the Scientific Committee of ECCO and coordinator of the European project "IBDChip". He is the author of more than 150 publications and 500 presentations at conferences and conferences.

Experience:

Digestive system specialist, completed the MIR training program and completed his residency in this specialty at the Provincial Hospital of Barcelona between 1993 and 1996.

Doctor of Medicine from the University of Barcelona with the qualification "Distinguished Diploma Unanimously". In 2001 he received the Distinguished Doctorate from the University of Barcelona.

Between 1997 and 1999, he completed his postgraduate training in the Gastroenterology Department of the Provincial Hospital of Barcelona. Subsequently, he completed two internships in the Gastroenterology Department of Case Western Reserve University in Cleveland, USA, between 2000 and 2003, where he conducted cutting-edge research in the field of gastroenterology.

Since 2004 he has been working in the Gastroenterology Service of the Provincial Hospital of Barcelona / IDIBAPS, focusing on the treatment and research of inflammatory bowel diseases.

He is the author of numerous publications, conference papers and book chapters both nationally and internationally.

Member of the Catalan Society of Gastroenterology, the Spanish Association of Gastroenterology, the Spanish Working Group on Crohn's Disease and Ulcerative Colitis and the American Gastroenterological Association.

Areas of special interest: storage rhythm disorders, chronic diarrhea, inflammatory bowel diseases (Crohn's disease and ulcerative colitis) and other causes of chronic intestinal inflammation.

Pichai Kittipanyaworakul, M.D.
Pichai Kittipanyaworakul, M.D.

INTERNAL MEDICINE / GASTROENTEROLOGIST AND HEPATOLOGIST

Graduation (M.D. From)

Bachelor of Medicine, Faculty of Medicine, Chiang Mai University

Certificates

Diploma in Internal Medicine, Faculty of Medicine, Chulalongkorn Memorial Hospital, Thai Red Cross Society

Diploma of Internal Medicine in Gastroenterology and Hepatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University

Current Positions

INTERNAL MEDICINE / GASTROENTEROLOGIST AND HEPATOLOGIST AT INTRARAT HOSPITAL

Dr. Victor Alexander Krol - Chief of Gastroenterology, Internal Medicine and Obesity Treatment Center at Martinus Hospital

Dr. Victor Alexander Krol is a highly qualified specialist, heading the departments of gastroenterology and internal medicine. With many years of experience and deep knowledge in his field, Dr. Krol has established himself as an outstanding expert, providing patients with comprehensive treatment and an individual approach. He actively uses the latest methods of diagnosis and treatment of diseases of the gastrointestinal tract, metabolism, as well as diseases of the cardiovascular and respiratory systems.

Dr. Krol is also the director of the certified Obesity Treatment Center at Martinus Hospital, which provides surgical and endoscopic treatments for obesity. The center uses advanced technology to diagnose and treat obesity (adiposis), including methods such as bariatric surgery, endoscopic weight loss, and specialized programs for patients with different stages of obesity. The center is certified to high standards and has excellent results in the treatment of this serious disease.

The Gastroenterology Department, headed by Dr. Krol, diagnoses and treats diseases of the stomach, intestines, liver, pancreas, and gallbladder. The doctors of the department use a wide range of methods, including endoscopic procedures, ultrasound, and other modern diagnostic technologies.

The Department of Internal Medicine covers a wide range of diseases, including cardiology, diabetology, infectology, and therapy of respiratory and renal diseases. Dr. Krol and his team provide a comprehensive approach to treatment using the most advanced methods of medicine.

Thanks to his high professionalism and humane approach to each patient, Dr. Krol deservedly enjoys the respect of colleagues and patients.

Білім және Академиялық Мәртебелер

• Хаджеттепе Университеті медицина факультеті – Медицина дәрежесі, 1992
• Башкент Университеті медицина факультеті – Жалпы хирургия резидентурасы, 1995
• Анкара Нумуне Оқу және Зерттеу Ауруханасы – Жалпы хирургия резидентурасы, 2000
• Газиантеп Университеті медицина факультеті – Жалпы хирургияның ассистент-профессоры, 2007
• Университетаралық Кеңес – Доцент, 2018
• Стамбул Айдын Университеті – Профессор, 2023
• Екінші бакалавр дәрежесі: Анадолу Университеті – Мемлекеттік басқару, 2008
• Магистр дәрежесі: Акдениз Университеті – Денсаулық құқығы, 2023

Pediatrician, Pediatric Gastroenterology and Nutrition Specialist

Education

Yeditepe University School of Medicine

Professor of Pediatrics (Chair of the Department)

2004 - 2007

Dokuz Eylül University School of Medicine

Pediatric Gastroenterology Sub-specialty

1995 – 1998

Hacettepe University School of Medicine

Pediatrics Instructor

1985 - 1987

Professional Experience

Ataşehir Florence Nightingale Hospital

Pediatrician, Pediatric Gastroenterology

2017 – Present

Kadıköy Şifa Ataşehir Hospital

Pediatric Gastroenterology and Nutrition

2013 – 2017 

Dokuz Eylül University School of Medicine

Professor of Pediatrics

1994 – 2004

Publications

Cevik N, Buyukgebiz B. Interaction between human blood group (ABO) substances and enteropathogenic

bacterial agents. Turk J Pediatr. 1987. Link

Buyukgebiz B, Ozalp I, Oran O. Investigation of serum vitamin A levels of children who had a history of

recurrent diarrhoea. J Trop Pediatrics. 1990. Link

Languages

Turkish: Native

English: Advanced

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.